Colorectal Cancer - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Colorectal Cancer - Pipeline Review, H2 2018’, provides an overview of the Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer

- The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects

- The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

3-V Biosciences Inc

4SC AG

Aadi Bioscience Inc

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abpro

Aclaris Therapeutics Inc

Adamed Sp z ...

3SBio Inc

3-V Biosciences Inc

4SC AG

Aadi Bioscience Inc

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abpro

Aclaris Therapeutics Inc

Adamed Sp z oo

ADC Therapeutics SA

Adhera Therapeutics

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced BioDesign

Advenchen Laboratories LLC

Agency for Science, Technology and Research

Agenus Inc

AlfaSigma SpA

Alkermes Plc

Alligator Bioscience AB

Allinky Biopharma SL

Almac Discovery Ltd

Alpine Immune Sciences Inc

ALX Oncology Inc

Amarin Corp Plc

amcure GmbH

Amgen Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Apogenix AG

Aposense Ltd

Arcus Biosciences Inc

Array BioPharma Inc

Arvinas Inc

Asana BioSciences LLC

Ascelia Pharma AB

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

B Cell Design SAS

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BeyondSpring Inc

Biocon Ltd

BioLineRx Ltd

Bionomics Ltd

Bionovis SA

Biosceptre International Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Cancer Prevention Pharmaceuticals Inc

Canget BioTekpharma LLC

Cantargia AB

Carna Biosciences Inc

CaroGen Corp

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellix Bio Pvt Ltd

Celltrion Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chengdu Kanghong Pharmaceuticals Group Co

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

ChoDang Pharm Co Ltd

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Cinnagen Co

Cleveland BioLabs Inc

COARE Biotechnology Inc

Compugen Ltd

Conatus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cytlimic Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Endor Technologies SL

Enochian Biosciences Inc

EntreChem SL

Enzene Biosciences Ltd

Enzo Biochem Inc

EpiThany Inc

Etubics Corp

Evelo Biosciences Inc

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

FLX Bio Inc

Fog Pharmaceuticals Inc

Forbius

Formosa Laboratories Inc

Forty Seven Inc

Fresenius SE & Co KGaA

F-star Biotechnology Ltd

Fujifilm Holdings Corporation

Fusion Antibodies plc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Colorectal Cancer - Overview 14

Colorectal Cancer - Therapeutics Development 15

Colorectal Cancer - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 13

Colorectal Cancer - Overview 14

Colorectal Cancer - Therapeutics Development 15

Colorectal Cancer - Therapeutics Assessment 83

Colorectal Cancer - Companies Involved in Therapeutics Development 115

Colorectal Cancer - Drug Profiles 257

Colorectal Cancer - Dormant Projects 2439

Colorectal Cancer - Discontinued Products 2462

Colorectal Cancer - Product Development Milestones 2468

Appendix 2479

List of Tables

List of Tables

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 85

Number ...

List of Tables

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 85

Number of Products under Development by Universities/Institutes, H2 2018 106

Products under Development by Companies, H2 2018 110

Products under Development by Universities/Institutes, H2 2018 146

Number of Products by Stage and Target, H2 2018 152

Number of Products by Stage and Mechanism of Action, H2 2018 166

Number of Products by Stage and Route of Administration, H2 2018 180

Number of Products by Stage and Molecule Type, H2 2018 182

Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018 183

Colorectal Cancer - Pipeline by 3SBio Inc, H2 2018 183

Colorectal Cancer - Pipeline by 4SC AG, H2 2018 184

Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H2 2018 184

Colorectal Cancer - Pipeline by AB Science SA, H2 2018 185

Colorectal Cancer - Pipeline by AbbVie Inc, H2 2018 185

Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2018 186

Colorectal Cancer - Pipeline by Abpro, H2 2018 186

Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018 186

Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2018 187

Colorectal Cancer - Pipeline by ADC Therapeutics SA, H2 2018 187

Colorectal Cancer - Pipeline by Adhera Therapeutics, H2 2018 188

Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2018 188

Colorectal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2018 189

Colorectal Cancer - Pipeline by Advanced BioDesign, H2 2018 189

Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018 189

Colorectal Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018 190

Colorectal Cancer - Pipeline by Agenus Inc, H2 2018 190

Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2018 191

Colorectal Cancer - Pipeline by Alkermes Plc, H2 2018 191

Colorectal Cancer - Pipeline by Alligator Bioscience AB, H2 2018 192

Colorectal Cancer - Pipeline by Allinky Biopharma SL, H2 2018 192

Colorectal Cancer - Pipeline by Almac Discovery Ltd, H2 2018 192

Colorectal Cancer - Pipeline by Alpine Immune Sciences Inc, H2 2018 193

Colorectal Cancer - Pipeline by ALX Oncology Inc, H2 2018 193

Colorectal Cancer - Pipeline by Amarin Corp Plc, H2 2018 194

Colorectal Cancer - Pipeline by amcure GmbH, H2 2018 194

Colorectal Cancer - Pipeline by Amgen Inc, H2 2018 195

Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2018 195

Colorectal Cancer - Pipeline by Apexigen Inc, H2 2018 195

Colorectal Cancer - Pipeline by Aphios Corp, H2 2018 196

Colorectal Cancer - Pipeline by Apogenix AG, H2 2018 196

Colorectal Cancer - Pipeline by Aposense Ltd, H2 2018 197

Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H2 2018 197

Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2018 198

Colorectal Cancer - Pipeline by Arvinas Inc, H2 2018 198

Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2018 199

Colorectal Cancer - Pipeline by Ascelia Pharma AB, H2 2018 199

Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018 199

Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2018 200

Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018 200

Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2018 201

Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202

Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2018 202

Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2018 203

Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203

Colorectal Cancer - Pipeline by Batu Biologics Inc, H2 2018 203

Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2018 204

Colorectal Cancer - Pipeline by Bayer AG, H2 2018 205

Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2018 205

List of Figures

List of Figures

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 84

Number ...

List of Figures

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 84

Number of Products under Development by Universities/Institutes, H2 2018 106

Number of Products by Top 10 Targets, H2 2018 151

Number of Products by Stage and Top 10 Targets, H2 2018 151

Number of Products by Top 10 Mechanism of Actions, H2 2018 165

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 165

Number of Products by Top 10 Routes of Administration, H2 2018 179

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 179

Number of Products by Top 10 Molecule Types, H2 2018 181

Number of Products by Stage and Top 10 Molecule Types, H2 2018 181

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports